CBR Inhibitors: Intraperitoneal injections of XL‐001, an inverse agonist of CB2R, ameliorated kidney injury, fibrosis, and inflammation in mice.[506] Rimonabant, another selective CB1R endocannabinoid receptor antagonist, was found to regulate macrophage infiltration and decrease MCP‐1 synthesis in mice model of renal fibrosis. This evidence concerns the gene CNR1 and renal fibrosis.